Literature DB >> 18505064

Development of cancer in patients with primary immunodeficiencies.

Katerina Salavoura1, Aggeliki Kolialexi, George Tsangaris, Ariadni Mavrou.   

Abstract

Primary immunodeficiencies (PIDs) are genetic disorders that predispose to frequent and severe infections, autoimmunity and cancer. The expanded life span of such patients increases the overall risk for developing cancer, which is now estimated at 4-25%. The type of malignancy depends on the primary immunodeficiency, the age of the patient and possible viral infection, suggesting that different pathogenetic mechanisms are implicated in each case. Non-Hodgkin's lymphomas predominate, accounting for 60% of cases. The PIDs known to be associated with increased incidence of malignancy are: common variable immunodeficiency, IgA deficiency and DNA repair disorders. During recent years other types have also been included, such as severe combined immunodeficiency (SCID) and Wiskott Aldrich syndrome (WAS).

Entities:  

Mesh:

Year:  2008        PMID: 18505064

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  47 in total

Review 1.  Microenvironment abnormalities and lymphomagenesis: Immunological aspects.

Authors:  Joseph G Taylor; John G Gribben
Journal:  Semin Cancer Biol       Date:  2015-07-29       Impact factor: 15.707

Review 2.  A Believer's Overview of Cancer Immunosurveillance and Immunotherapy.

Authors:  Olivera J Finn
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

3.  Leveraging premalignant biology for immune-based cancer prevention.

Authors:  Avrum Spira; Mary L Disis; John T Schiller; Eduardo Vilar; Timothy R Rebbeck; Rafael Bejar; Trey Ideker; Janine Arts; Matthew B Yurgelun; Jill P Mesirov; Anjana Rao; Judy Garber; Elizabeth M Jaffee; Scott M Lippman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-16       Impact factor: 11.205

Review 4.  Primary immunodeficiencies and their associated risk of malignancies in children: an overview.

Authors:  Samuele Renzi; Karin Petra Sabine Langenberg-Ververgaert; Nicolas Waespe; Salah Ali; Jack Bartram; Orli Michaeli; Julia Upton; Michaela Cada
Journal:  Eur J Pediatr       Date:  2020-03-11       Impact factor: 3.183

5.  Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinoma.

Authors:  Nate N Waldron; Seunguk Oh; Daniel A Vallera
Journal:  Oral Oncol       Date:  2012-07-20       Impact factor: 5.337

Review 6.  Post-transplantation malignancies: here today, gone tomorrow?

Authors:  Edward K Geissler
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

7.  Serial changes in lymphocyte subsets in patients with newly diagnosed high grade astrocytomas treated with standard radiation and temozolomide.

Authors:  Jian L Campian; Anna F Piotrowski; Xiaobu Ye; Frances T Hakim; Jeremy Rose; Xiao-Yi Yan; Yao Lu; Ronald Gress; Stuart A Grossman
Journal:  J Neurooncol       Date:  2017-07-29       Impact factor: 4.130

8.  Common variable immunodeficiency.

Authors:  Jonathan S Tam; John M Routes
Journal:  Am J Rhinol Allergy       Date:  2013 Jul-Aug       Impact factor: 2.467

9.  Hodgkin lymphoma in 2 children with chronic granulomatous disease.

Authors:  Saul Oswaldo Lugo Reyes; Felipe Suarez; Rose-Marie Herbigneaux; Hélène Pacquement; Yves Réguerre; Jean-Pierre Rivière; Maylis de Suremain; Yoann Rose; Jacqueline Feinberg; Nizar Malahoui; Alain Fischer; Stéphane Blanche; Jean-Laurent Casanova; Capucine Picard; Jacinta Bustamante
Journal:  J Allergy Clin Immunol       Date:  2010-12-18       Impact factor: 10.793

Review 10.  Repertoire development and the control of cytotoxic/effector function in human gammadelta T cells.

Authors:  Elizabeth M Urban; Andrei I Chapoval; C David Pauza
Journal:  Clin Dev Immunol       Date:  2010-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.